IMPLANET announced that it has finalized the partnership with L&K BIOMED Co. Ltd. In January, IMPLANET entered into a distribution agreement with Aegis Spine, L&K BIOMED's US subsidiary, under which it can harness the expertise of Aegis Spine's team for the commercialization of its products in the United States, a priority market for the Company. In line with the previous announcement, the strategic alliance between IMPLANET and L&K BIOMED has now been finalized, with cross-distribution agreements covering their respective products in Asia and Europe.

In the United States: IMPLANET America will pool its resources with those of Aegis Spine to accelerate the commercialization of its JAZZ® platform. The development of existing and complementary solutions incorporating both companies' technologies will be a key lever for this. In Asia and Oceania: L&K BIOMED will distribute the JAZZ® platform alongside its product range.

Initially, in addition to the South Korean market, the aim is to expand jointly into the Japanese market, the world's second-largest market for medical technologies. Subsequently, they will target the Chinese market. In Europe: IMPLANET will distribute L&K BIOMED's products, which complement the JAZZ® platform, in France, the United Kingdom and Germany, with a view to establishing itself as a major player in these markets.